NCT07509996Not yet recruiting
Risk Factors Affecting Growth in Thalassemic Children at AUCH
The Effect of Different Risk Factors on Growth Parameters of Thalassemic Patients in Assiut University Children Hospital
Source: ClinicalTrials.gov · Last updated 3 Apr 2026
Brief summary (registry, in English)
Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis and severe anemia, necessitating lifelong blood transfusions(1,2). Regular transfusions lead to iron overload, a primary driver of growth retardation in affected children. Iron accumulation in tissues like the pituitary and liver disrupts growth hormone secretion and insulin-like growth factor-1 production.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 85 (estimated)
- First submitted
- 28 Mar 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Assiut University
- Diseases
- Thalassaemia
- NCT number
- NCT07509996
What you commit to
- Study type: Observational
- Planned participants: 85
- From 1 Apr 2026 to the primary completion date, 1 Apr 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- • Children with other types of thalassemia.
- Presence of congenital diseases, chronic illnesses other than thalassemia (e.g., malignancy, tuberculosis, chronic hepatitis, congenital heart disease, chronic renal failure, epilepsy, diabetes mellitus), or primary endocrinopathies.
- Patients with other causes of short stature, such as hereditary bone dysplasia or systemic disorders.
Who the study is looking for
- Children aged 1 to 18 years diagnosed with β-thalassemia major based on hemoglobin electrophoresis or high-performance liquid chromatography (HPLC).
- Receiving regular blood transfusions as part of standard management at AUCH.
- Attending the hematology unit for at least one year prior to enrollment.
Age in the registry: 12 months to 18 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.